A randomized, double-blind, parallel-group study conducted under in-house blinding conditions to determine the safety, tolerability and efficacy of aprepitant regimen compared to ondansetron regimen for the prevention of chemotherapy induced nausea and vomiting (CINV) associated with high dose cisplatin in cycle 1

Trial Profile

A randomized, double-blind, parallel-group study conducted under in-house blinding conditions to determine the safety, tolerability and efficacy of aprepitant regimen compared to ondansetron regimen for the prevention of chemotherapy induced nausea and vomiting (CINV) associated with high dose cisplatin in cycle 1

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2017

At a glance

  • Drugs Aprepitant (Primary) ; Dexamethasone; Ondansetron; Ondansetron
  • Indications Chemotherapy-induced nausea and vomiting; Nausea; Nausea and vomiting; Vomiting
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 26 Jan 2010 Company added as trial affiliate, primary endpoint identified as Patient vomiting as reported by ClinicalTrials.gov.
    • 16 Sep 2008 Results presented at ESMO
    • 31 Aug 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top